Researchers at the University of California San Diego report that a simple blood test measuring the biomarker phosphorylated tau 217, known as p-tau217, may flag dementia risk decades before symptoms appear, based on long-term tracking of older women; the study suggests this marker is “strongly linked” to later cognitive decline and points toward less invasive screening and targeted prevention research.
The team analyzed stored blood samples from 2,766 participants enrolled in a large memory study in the late 1990s. Those women were 65 to 79 years old and showed no signs of cognitive decline when the study began.
After following participants for up to 25 years, investigators found that p-tau217 was “strongly associated” with later development of mild cognitive impairment and dementia. Women with higher baseline p-tau217 were “much more likely” to develop dementia over the follow-up period.
One important passage from the lead author framed the potential: “The key takeaway is that our study suggests it may be possible to detect risk of dementia two decades in advance using a simple blood test in older women,” said Aladdin H. Shadyab, an associate professor of public health and medicine at UC San Diego. He added, “Our findings show that the blood biomarker p-tau217 could help identify individuals at higher risk for dementia long before symptoms begin.”
The predictive strength was not uniform across the group. Women older than 70 who had elevated p-tau217 experienced poorer cognitive outcomes than those under 70, and carriers of the APOE ε4 gene showed heightened risk, consistent with known genetic vulnerability to Alzheimer’s disease.
Interestingly, p-tau217 proved a stronger predictor among the women who had been randomized to receive combined estrogen and progestin hormone therapy compared with those given placebo. That interaction hints at complex links between hormones, aging biology, and the cascade that leads to dementia.
Senior author Linda K. McEvoy emphasized the practical upside of blood testing: “Blood-based biomarkers like p-tau217 are especially promising because they are far less invasive and potentially more accessible than brain imaging or spinal fluid tests.” She added, “This is important for accelerating research into the factors that affect the risk of dementia and for evaluating strategies that may reduce risk.”
Despite the promise, researchers caution that blood testing for Alzheimer’s or dementia is not yet ready for routine screening in people without symptoms. Additional work is required to confirm findings, refine thresholds, and understand how p-tau217 performs across diverse populations and clinical settings.
The study authors recommend further research to explore how genetics, hormone therapy status, and other age-related medical conditions might modify plasma p-tau217’s predictive value. They also noted limits to generalizability, stating, “The study examined only older women, so the findings may not necessarily apply to men or younger populations.” They added, “We also examined overall dementia outcomes rather than specific subtypes such as Alzheimer’s disease.”
The implications are twofold: a reliable blood marker could shift research and care toward earlier intervention, and it could make large-scale screening or trials far easier and cheaper to run. At the same time, clinicians and policymakers must resist the rush to clinical adoption until evidence clarifies who benefits and how best to act on elevated biomarker results.
For now, p-tau217 stands out as a leading candidate in the move to blood-based neurology. The study’s long follow-up period and large cohort give weight to its findings, but translating that into clinical practice will take coordinated validation, attention to equity, and carefully designed trials that test prevention strategies in people identified early by the assay.
